Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315499 | 0.78 | PABPC1 (0.54) | — | |
| SCHEMBL13727383 | 0.74 | P2RX7 (0.58) | P2RX7EPHX2 | |
| SCHEMBL3021583 | 0.73 | P2RX7 (0.57) | P2RX7EPHX2CA2 | |
| SCHEMBL13043108 | 0.73 | P2RX7 (0.59) | P2RX7 | |
| SCHEMBL14764889 | 0.72 | P2RX7 (0.73) | P2RX7EPHX2CA2 | |
| SCHEMBL4500841 | 0.72 | P2RX7 (0.59) | P2RX7 | |
| SCHEMBL22372103 | 0.72 | HIF1A (0.48) | — | |
| SCHEMBL3454922 | 0.72 | P2RX7 (1.00) | P2RX7EPHX2CA2 | |
| SCHEMBL6084856 | 0.71 | P2RX7 (0.58) | P2RX7 | |
| SCHEMBL17483924 | 0.71 | P2RX7 (0.75) | P2RX7EPHX2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104844578-B | 5 membered heterocyclic amides and relevant compound | H.隆德贝克有限公司 | 2018-06-19 | — | — | CN | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| CN-104844578-A | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | NEUROGEN CORP | 2015-08-19 | — | — | CN | disclosed |
| CN-101711245-B | 5-membered heterocyclic amides and related compounds | LUNDBECK & CO AS H | 2015-03-25 | — | — | CN | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| CN-101711245-A | 5-membered heterocyclic amides and related compounds | NEUROGEN CORP | 2010-05-19 | — | — | CN | disclosed |
| EP-2178865-A2 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | Lundbeck, H., A/S (DK) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009012482-A2 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | H.LUNDBECK A/S (DK) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012482-A2 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | H.LUNDBECK A/S (DK) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | GPR35, HCAR2, HCAR1 | P2RX7 268/4885EPHX2 2701/4885CA2 3303/4885 |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | GPR35, HCAR2, HCAR1 | P2RX7 268/4885EPHX2 2701/4885CA2 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.